PMID- 33656014
OWN - NLM
STAT- MEDLINE
DCOM- 20210304
LR  - 20220531
IS  - 1699-3993 (Print)
IS  - 1699-3993 (Linking)
VI  - 57
IP  - 2
DP  - 2021 Feb
TI  - An update on dapagliflozin for the treatment of heart failure.
PG  - 77-88
LID - 10.1358/dot.2021.57.2.3223386 [doi]
AB  - Heart failure (HF) is a substantial source of morbidity and mortality. Several 
      clinical trials have reported a significant HF benefit of sodium/glucose 
      cotransporter 2 (SGLT2) inhibitors in patients with type 2 diabetes. In 2019, the 
      Food and Drug Administration (FDA) approved dapagliflozin to reduce 
      hospitalization risk for HF in adults with type 2 diabetes and established 
      cardiovascular disease or risk factors. Regardless of the presence of diabetes, 
      the recent DAPA-HF study reported a significant relative risk (RR) reduction with 
      dapagliflozin in the composite primary outcome of worsening HF or death from 
      cardiovascular causes in patients with New York Heart Association (NYHA) class 
      II, III or IV HF and an ejection fraction of 40%. There was a 30% RR reduction in 
      hospitalizations for HF, 57% RR reduction in urgent HF visits, and 18% RR 
      reduction in cardiovascular death. These results led the FDA to approve 
      dapagliflozin in 2020 for the treatment of HF with reduced ejection fraction 
      (NYHA class II-IV) in adults with and without type 2 diabetes. This article 
      summarizes HF outcomes from large clinical trials of SGLT2 inhibitors and focuses 
      on dapagliflozin's HF benefits. The review also covers potential mechanisms of HF 
      benefit and the safety profile of dapagliflozin in patients with HF.
CI  - Copyright 2021 Clarivate Analytics.
FAU - Akinci, B
AU  - Akinci B
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, Dokuz 
      Eylul University, Faculty of Medicine, Izmir, Turkey. barisakincimd@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Spain
TA  - Drugs Today (Barc)
JT  - Drugs of today (Barcelona, Spain : 1998)
JID - 101160518
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Glucosides)
RN  - 1ULL0QJ8UC (dapagliflozin)
SB  - IM
MH  - Adult
MH  - Benzhydryl Compounds/adverse effects
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Glucosides/adverse effects
MH  - *Heart Failure/drug therapy
MH  - Humans
OTO - NOTNLM
OT  - Cardiovascular drugs
OT  - Dapagliflozin
OT  - Heart failure therapy
OT  - Sodium/glucose cotransporter 2 (SGLT2) inhibitors
EDAT- 2021/03/04 06:00
MHDA- 2021/03/05 06:00
CRDT- 2021/03/03 08:53
PHST- 2021/03/03 08:53 [entrez]
PHST- 2021/03/04 06:00 [pubmed]
PHST- 2021/03/05 06:00 [medline]
AID - 3223386 [pii]
AID - 10.1358/dot.2021.57.2.3223386 [doi]
PST - ppublish
SO  - Drugs Today (Barc). 2021 Feb;57(2):77-88. doi: 10.1358/dot.2021.57.2.3223386.